Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSSTop-line ...
rheumatologyadvisor4d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Surgical treatment of carotid artery disease reduces stroke risk
Carotid artery disease, a progressive buildup of calcium deposits and cholesterol in the primary artery supplying blood to the brain, poses a risk of stroke but there are a few ways to treat it. Dr.
Too Old to Operate12d
Intranasal Niclosamide Failed to Prevent Symptomatic COVID-19
The following is a summary of “Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V ...
Morningstar14d
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) In the MOTION Phase 3 study, ROMVIMZA met primary ...
Monthly Prescribing Reference11d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...